Pfizer’s Vyndaqel slows neurodegenerative disease, analysis shows
A new analysis of data pooled from three clinical trials backs early intervention with Pfizer’s Vyndaqel in patients with the rare neurodegenerative disease transthyretin familial amyloid polyneuropathy (TTR-FAP).
Read More
